Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Ordinary Shares
-
Shares outstanding
-
18.4M
-
Number of holders
-
22
-
Total 13F shares, excl. options
-
2.66M
-
Shares change
-
+6.12K
-
Total reported value, excl. options
-
$7.52M
-
Value change
-
-$53.8K
-
Number of buys
-
3
-
Number of sells
-
-8
-
Price
-
$2.83
Significant Holders of CASI Pharmaceuticals, Inc. - Ordinary Shares (CASI) as of Q4 2024
26 filings reported holding CASI - CASI Pharmaceuticals, Inc. - Ordinary Shares as of Q4 2024.
CASI Pharmaceuticals, Inc. - Ordinary Shares (CASI) has 22 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2.66M shares
of 18.4M outstanding shares and own 14.45% of the company stock.
Largest 10 shareholders include Foresite Capital Management VI LLC (1.33M shares), VR Adviser, LLC (987K shares), Woodline Partners LP (99.7K shares), Wellington Shields Capital Management, LLC (85.8K shares), ADAR1 Capital Management, LLC (46.3K shares), RENAISSANCE TECHNOLOGIES LLC (39.4K shares), Wellington Shields & Co., LLC (30.1K shares), GEODE CAPITAL MANAGEMENT, LLC (19.4K shares), UBS Group AG (11.3K shares), and Royal Bank of Canada (6.9K shares).
This table shows the top 22 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.